From: Restrictive annuloplasty or replacement on reverse remodeling for nonischemic dilated cardiomyopathy
Annuloplasty | |||
---|---|---|---|
LVRR | No LVRR | p value | |
Variables | (n = 25) | (n = 22) | |
Clinical data | |||
Age, years | 63 ± 9 | 64 ± 9 | 0.64 |
Male sex | 18 (72%) | 16 (73%) | 0.96 |
Medical history and presentation at baseline | |||
NYHA functional class III or IV | 21 (84%) | 22 (100%) | 0.020 |
Logistic EuroSCORE II | 4.3 [2.6, 8.5] | 8.0 [5.3, 13.5] | 0.007 |
Chronic kidney disease stage 4 or 5 | 7 (28%) | 9 (41%) | 0.35 |
Atrial fibrillation | 18 (72%) | 6 (27%) | 0.002 |
Diabetes mellitus | 5 (20%) | 8 (36%) | 0.21 |
Hypertension | 8 (32%) | 4 (18%) | 0.27 |
Previous CRT | 2 (8%) | 7 (32%) | 0.035 |
Medication at baseline | |||
Beta-blocker | 18 (72%) | 17 (72%) | 0.68 |
ACE inhibitor or angiotensin-receptor blocker | 15 (60%) | 12 (55%) | 0.71 |
Diuretic | 21 (84%) | 19 (86%) | 0.82 |
Echocardiography | |||
LV end-diastolic dimension, mm | 67 ± 10 | 73 ± 10 | 0.039 |
LV end-systolic dimension, mm | 58 ± 10 | 65 ± 11 | 0.018 |
LV end-diastolic volume index, ml/m2 | 147 ± 50 | 179 ± 50 | 0.033 |
LV end-systolic volume index, ml/m2 | 107 ± 43 | 141 ± 47 | 0.013 |
LV ejection fraction, % | 29 ± 8 | 25 ± 8 | 0.065 |
Left atrial dimension, mm | 50 ± 8 | 48 ± 9 | 0.33 |
Mitral regurgitation grade | 0.49 | ||
Moderate | 10 (40%) | 11 (50%) | |
Severe | 15 (60%) | 11 (50%) | |
Tricuspid regurgitation grade | 0.11 | ||
Mild | 11 (44%) | 9 (41%) | |
Moderate | 9 (36%) | 5 (23%) | |
Severe | 3 (12%) | 2 (9%) | |
Surgical data | |||
Papillary muscle approximation | 11 (44%) | 11 (50%) | 0.68 |
Concomitant procedures | |||
Tricuspid valve repair | 20 (80%) | 13 (59%) | 0.12 |
Atrial maze | 10 (40%) | 6 (27%) | 0.36 |